Zynex, Inc. (NASDAQ:ZYXI - Get Free Report) CEO Thomas Sandgaard sold 2,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $8.37, for a total value of $16,740.00. Following the completion of the sale, the chief executive officer now directly owns 14,605,662 shares of the company's stock, valued at $122,249,390.94. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Thomas Sandgaard also recently made the following trade(s):
- On Monday, November 11th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $9.09, for a total transaction of $18,180.00.
- On Friday, November 8th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.77, for a total transaction of $17,540.00.
- On Wednesday, November 6th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.82, for a total value of $17,640.00.
- On Monday, November 4th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.67, for a total value of $17,340.00.
- On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.63, for a total value of $17,260.00.
- On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.92, for a total value of $17,840.00.
Zynex Price Performance
There is a little known company that is changing warfare
From Reticulate | Ad
With geo - political instability around the world investors are flocking to defense contract stocks.
There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.
Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t
Zynex stock opened at $8.13 on Thursday. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. The firm has a market capitalization of $258.94 million, a PE ratio of 54.20 and a beta of 0.53. The firm's 50-day simple moving average is $8.22 and its 200 day simple moving average is $8.92. Zynex, Inc. has a 52 week low of $7.15 and a 52 week high of $13.77.
Zynex (NASDAQ:ZYXI - Get Free Report) last announced its earnings results on Thursday, October 24th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.01. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The firm had revenue of $49.97 million during the quarter, compared to the consensus estimate of $50.83 million. The firm's revenue for the quarter was up .1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.10 EPS. On average, equities research analysts predict that Zynex, Inc. will post 0.2 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on ZYXI. HC Wainwright raised their target price on shares of Zynex from $16.00 to $17.00 and gave the stock a "buy" rating in a research note on Friday, October 25th. Royal Bank of Canada reduced their price target on shares of Zynex from $12.00 to $11.00 and set an "outperform" rating for the company in a research report on Tuesday, October 8th.
View Our Latest Report on ZYXI
Institutional Investors Weigh In On Zynex
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quest Partners LLC lifted its holdings in shares of Zynex by 131.3% during the 3rd quarter. Quest Partners LLC now owns 29,898 shares of the company's stock valued at $244,000 after acquiring an additional 16,972 shares in the last quarter. Gladius Capital Management LP raised its position in shares of Zynex by 53.4% in the 3rd quarter. Gladius Capital Management LP now owns 5,002 shares of the company's stock valued at $41,000 after purchasing an additional 1,742 shares in the last quarter. Royce & Associates LP boosted its stake in Zynex by 9.2% during the 3rd quarter. Royce & Associates LP now owns 257,291 shares of the company's stock valued at $2,099,000 after acquiring an additional 21,781 shares during the last quarter. GSA Capital Partners LLP grew its position in shares of Zynex by 72.7% in the 3rd quarter. GSA Capital Partners LLP now owns 79,930 shares of the company's stock worth $652,000 after acquiring an additional 33,649 shares in the last quarter. Finally, Janney Montgomery Scott LLC grew its position in shares of Zynex by 22.3% during the 3rd quarter. Janney Montgomery Scott LLC now owns 144,439 shares of the company's stock valued at $1,179,000 after buying an additional 26,368 shares during the last quarter. 29.68% of the stock is currently owned by institutional investors and hedge funds.
Zynex Company Profile
(
Get Free Report)
Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
